The anti-platelet approach targeting the fibrinogen ligand of the GPIIb/IIIa receptor

Journal of Peptide Science

Volumn 10, Issue 10, 2004, Pages 589-602

  Tsikaris, Vassilios ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

IIb 3 receptor; Fibrinogen blockers; GPIIb IIIa binding domains; Integrin inhibitors; Platelet aggregation inhibitors

Indexed keywords

AMINO ACID; ANTITHROMBOCYTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BETA INTEGRIN; DISINTEGRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LIGAND; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PEPTIDE DERIVATIVE; PROTEIN SUBUNIT; SYNTHETIC PEPTIDE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR;

AMINO ACID SEQUENCE; CLINICAL TRIAL; DRUG BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; GENE MUTATION; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RECEPTOR BLOCKING; REVIEW; THROMBOCYTE AGGREGATION; THROMBUS; TREATMENT OUTCOME;

BINDING SITES; DRUG DESIGN; FIBRINOGEN; HUMANS; LIGANDS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

THROMBUS;

EID: 6944221257     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.603     Document Type: Review

References (126)

1. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549-554.
2. Loftus JC, Smith JW, Ginsberg MH. Integrin-mediated cell adhesion: The extracellular face. J. Biol. Chem. 1994; 269: 25 235-25 238.
3. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J. Biol. Chem. 1979; 254: 5357-5363.
4. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-497.
5. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J. Biol. Chem. 2000; 275: 21 785-21 788.
6. Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins and platelets. Thromb. Haemost. 1988; 59: 1-6.
7. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp specific adhesion receptors. Science 1986; 231: 1559-1562.
8. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. Clin. Invest. 1979; 64: 1393-1401.
9. 3 integrin reconstituted into planar lipid bilayers. J. Biol. Chem. 1993; 268: 6800-6808.
10. 3 and its ligand and induces selective movements of ligand-occupied integrin. J. Biol. Chem. 1996; 271 7004-7011.
11. Coller BS. Platelets and thrombolytic therapy. N. Engl. J. Med. 1990; 322: 33-42.
12. Gresele P, Agnelli G. Novel approaches to the treatment of thrombosis. Trends Pharmacol. Sci. 2002; 23: 25-32.
13. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb. Res. 2002; 106: V275-V284.
14. Geiger J. Inhibitors of platelet signal transduction as anti-aggregatory drugs. Exp. Opin. Invest. Drugs 2001; 10: 865-890.
15. Pierschbacher MD, Ruoslahti E, Sundelin J, Lind P, Peterson PA. The cell attachment domain of fibronectin. Determination of the primary structure. J. Biol. Chem. 1982; 257: 9593-9597.
16. Lam SCT, Plow EF, Ginsberg MH. Evidence that arginyl-glycyl-aspartate peptides and fibrinogen γ chain peptides share a common binding site on platelets. J. Biol. Chem. 1987; 262: 947-950.
17. Gartner TK, Bennett JS. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding in activated platelets. J. Biol. Chem. 1985; 260: 11891-11894.
18. Plow EF, Srouji AH, Meyer D, Marguerie G, Ginsberg MH. Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J. Biol. Chem. 1984; 259: 5388-5391.
19. Andrieux A, Hudry-Glergeon G, Ryckewaert J-J, Chapel A, Ginsberg MH, Plow EF, Marguerie G. Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GPIIbIIIa. J. Biol. Chem. 1989; 264: 9258-9265.
20. Ojima I, Chakravarty S, Dong Q. Antithrombotic agents: From RGD to peptide mimetics. Bioorg. Med. Chem. 1995; 3:337-360.
21. Craig WS, Cheng S, Mullen DG, Blevitt J, Pierschbacher MD. Concept and progress in the development of RGD-containing peptide pharmaceuticals. Biopolymers 1995; 37: 157-175.
22. Stavrakoudis A, Bizos G, Eleftheriadis D, Kouki A, Panou-Pomonis E, Sakarellos-Daitsiotis M, Sakarellos C, Tsoukatos D, Tsikaris V. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis and structure-function relationships. Biopolymers 2001; 56: 20-26.
23. Casserly IP, Topol EJ. Glycoprotein IIb/IIIa antagonists - from bench to practice. Cell. Mol. Life Sci. 2002; 59: 478-500.
24. 3 integrin antagonists. J. Pharmacol. Exp. Ther. 2001; 296: 690-696.
25. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-231.
26. Scarborough RM, Kleiman NS, Philips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999; 100: 437-444.
27. Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 2000; 102: e76-e80.
28. 1 integrins. J. Biol. Chem. 1994; 269: 20 233-20 238.
29. Samanen J, Ali F, Romoff T, Calvo R, Sorenson E, Vasco J, Storer B, Berry D, Bennett D, Strohsacker M, Powers D, Stadel J, Nichols A. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J. Med. Chem. 1991; 34 3114-3125.
30. 3 antagonists. J. Am. Chem. Soc. 1996; 118: 7461-7472.
31. Ali F, Bennett D, Calvo R, Elliott J, Hwang S-M, Ku T, Lago M, Nichols A, Romoff T, Shah D, Vasko J, Wong A, Yellin T, Yuan C-K, Samanen J. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of platelet fibrinogen receptor and platelet aggregation. J. Med. Chem. 1994; 37: 769-780.
32. Bach A, Eyermann C, Gross J, Bower M, Harlow R, Weber P, DeGrado W. Structural studies of a family of high affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. 1994; 116: 3207-3219.
33. Schabbert S, Pierschbacher M, Mattern R-H, Goodman M. Incorporation of (2S,3S) and (2S,3R) β-methyl aspartic acid into RGD-containing peptides. Bioorg. Med. Chem. 2002; 10: 3331-3337.
34. McLance MA, Marcinkiewcz C, Vijay-Kumar S, Wierzbicka-Patynowski I, Niewiarowski S. Viper venom disintegrins and related molecules. Proc. Soc. Exp. Biol. Med. 1998; 219: 109-119.
35. D'Souza SE, Ginsberg MH, Lam SC-T, Plow EF. Chemical cross-linking of arginyl-glycyl-aspartic acid peptides to an adhesion receptor on platelets. J. Biol. Chem. 1988; 263: 3943-3951.
36. Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B. Identification of low molecular weight GPIIb/IIIa antagonists that bind preferentially to activated platelets. J. Pharmacol. Exp. Ther. 1998; 285: 1317-1326.
37. Frelinger III AL, Cohen I, Plow EF, Smith MA, Roberts J, Lam SC-T, Ginsberg MH. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J. Biol. Chem. 1990; 265: 6346-6352.
38. Kouns WC, Wall CD, White MM, Fox CF, Jennings LK. A conformation-dependent epitope of human platelet glycoprotein IIIa. J. Biol. Chem. 1990; 265: 20 594-20 601.
39. 3 conformations. J. Biol. Chem. 1999; 274: 12 945-12 949.
40. 3 and elicit different functional responses. J. Biol. Chem. 1999; 274: 16 923-16 932.
41. Mondoro TH, White MM, Jennings LK. Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization. Blood 2000; 96: 2487-2495.
42. Peter K, Stranb A, Kohler B, Volkmann M, Schwarz M, Kubler W, Bode C. Platelet activation as a potential mechanism of GPIIb/IIIa inhibitor-induced thrombocytopenia. Am. J. Cardiol. 1999; 84: 519-524.
43. Peter K, Schwarz M, Nordt T, Bode C. Intrinsic activating properties of GP IIb/IIIa blockers. Thromb. Res. 2001; 103: S21-S27.
44. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists. A metaanalysis of phase III multicenter randomized trials. Circulation 2001; 103: 201-206.
45. 3) inhibitors. Blood 1998; 92 3240-3249.
46. Peter K, Schwarz M, Bode C. Activating effects of GPIIb/IIIa blockers: An intrinsic consequence of ligand mimetic properties. Circulation 2002; 105: E180-E181.
47. Frelinger III AL, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation 2001; 104: 1374-1379.
48. Zolotarjova NI, Hollis GF, Wynn R. Unusually stable and long-lived ligand-induced conformations of integrins. J. Biol. Chem. 2001; 276: 17063-17068.
49. 3 integrin conformation and oligomerization. Biochemistry 1999; 38 14 461-14 474.
50. 3. J. Biol. Chem. 1999; 274: 4633-4639.
51. 3. J. Biol. Chem. 2002; 277: 39 899-39 908.
52. 3. Roles of the transmembrane and cytoplasmic domains. Proc. Natl Acad. Sci. USA 2001; 98: 12 462-12 467.
53. 3. J. Biol. Chem. 1993; 268: 23 087-23 092.
54. 3 (platelet GPIIb-IIIa). Cell 1991; 65: 409-416.
55. 3's open conformation. Protein Sci. 2001; 10: 1614-1626.
56. 3. J. Biol. Chem. 2003; 278: 3417-3426.
57. 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J. Biol. Chem. 1991; 266: 17 106-17 111.
58. 3 by inducing an allosteric change in the amino-terminal portion of α IIb. J. Biol. Chem. 2001; 276: 13 975-13 981.
59. 3 clustering in living cells. J. Biol. Chem. 2003; 278: 15 217-15 224.
60. Mayo KH, Fan F, Beavers MP, Eckardt A, Keane P, Hoekstra WJ, Andrade-Gordon P. RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen γ-chain C-terminal peptide. FEBS Lett. 1996; 378: 79-82.
61. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of α-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc. Res. 2000; 45: 437-446.
62. 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J. Biol. Chem. 1990; 265: 12 267-12 271.
63. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58: 945-953.
64. Farell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J. Biol. Chem. 1994; 269: 226-231.
65. Farell DH, Thiagarajan P. Chung DW, Davie EW. Role of fibrinogen α and γ chain sites in platelet aggregation. Proc. Natl Acad. Sci. USA 1992; 89: 10 729-10 732.
66. D'Souza SE, Ginsberg MH, Burke TA, Plow EF. The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its α subunit. J. Biol. Chem. 1990; 265: 3440-3446.
67. Kouns WC, Hadvary P, Haering P, Steiner B. Conformational modulation of purified glycoprotein (GP)IIb-IIIa allows proteolytic generation of inactive GPIIb-IIIa. J. Biol. Chem. 1992; 267: 18 844-18 851.
68. Lam SC-T. Isolation and characterization of a chymotryptic fragment of platelet glycoprotein IIb-IIIa retaining Arg-Gly-Asp binding activity. J. Biol. Chem. 1992; 267: 5649-5655.
69. IIbβ. J. Biol. Chem. 1996; 271: 2033-2039.
70. Santoro SA, Lawing WJ. Competition for related but nonidentical binding sites on the glycoprotein IIb-IIIa complex by peptides derived from platelet adhesive proteins. Cell 1987; 48 867-873.
71. D'Souza SE, Ginsberg MH, Burke TA, Lam SC-T, Plow EF. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science 1988; 242: 91-93.
72. Smith JW, Cheresh DA. The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the β subunit. J. Biol. Chem. 1988; 263: 18 726-18 731.
73. 3 subunit is sensitive to stimulation. J. Biol. Chem. 1991; 266: 14 202-14 207.
74. 3 subunit: Cation displacement is involved in ligand binding. Cell 1994; 79: 659-667.
75. 3) by terbium luminescence. Biochemistry 1994; 33 12 238-12 246.
76. Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J. Cell Biol. 1995; 130: 1189-1196.
77. Calvete JJ, Arias J, Alvarez MV, Lopez MM, Henschen A, Gonzalez-Rodriguez J. Further studies on the topography of the N terminal region of human platelet glycoprotein IIIa. Localization of monoclonal antibody epitopes and the putative fibrinogen-binding sites. Biochem. J. 1991; 247: 457-463.
78. Calvete JJ, Schäfer W, Mann K, Henschen A, González-Rodríguez J. Localization of the cross-linking sites of RGD and KQAGDV peptides on the isolated fibrinogen receptor, the human platelet integrin glycoprotein IIb/IIIa. Influence of peptide length. Eur. J. Biochem. 1992; 206: 759-765.
79. Charo IF, Nannizzi L, Philips DR, Hsu MA, Scarborough RM. Inhibition of fibrinogen binding to GPIIb-IIIa by a GPIIIa peptide. J. Biol. Chem. 1991; 266: 1415-1421.
80. Argraves WS, Suzuki S, Arai H, Thompson K, Pierschbacher MD, Ruoslahti E. Amino acid sequence of the human fibronectin receptor. J. Cell Biol. 1987; 105: 1183-1190.
81. Kishimoto TK, O'Connor K, Lee A, Roberts TM, Srpinger TA. Cloning of the β subunit of the leukocyte adhesion proteins: homology to an extracellular matrix receptor defines a novel supergene family. Cell 1987; 48: 681-690.
82. 3 (GPIIb-IIIa) and inhibit ligand binding. J. Biol. Chem. 1993; 268: 6870-6873.
83. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J. Biol. Chem. 1985; 260: 11 107-11 114.
84. Cook JJ, Trybulec M, Lasz EC, Khan S, Niewiarowski S. Binding of glycoprotein IIIa-derived peptide 217-231 to fibrinogen and von Willebrand factors and its inhibition by platelet glycoprotein IIb/IIIa complex. Biochim. Biophys. Acta 1992; 1119: 312-321.
85. 3 Integrin derived peptide 217-230 inhibits fibrinogen binding and platelet aggregation: significance of RGD sequences and fibrinogen Aα-chain. Biochem. Biophys. Res. Commun. 1993; 190: 118-124.
86. 3 complex and with fibrinogen Aα -chain. Thromb. Res. 1997; 85: 115-126.
87. 3 provides a ligand recognition and binding domain for the γ-chain of fibrinogen that is independent of platelet activation. Blood 1996; 87: 592-601.
88. 3 subunit. J. Biol. Chem. 2002; 277: 11 126-11 134.
89. 3. J. Biol. Chem. 2000; 275: 7795-7802.
90. 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science 1990; 249: 915-918.
91. 3 (GPIIb-IIIa) receptor function. J. Biol. Chem. 1994; 269: 20 913-20 919.
92. 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J. Biol. Chem. 1992; 267: 3789-3794.
93. Lanza F, Stierle A, Fournier D, Morales M, Andre G, Nurden AT, Cazenave JP. A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg → 214Trp mutation. J. Clin. Invest. 1992; 89: 1995-2004.
94. 3 integrins by swapping a short diverse sequence of the β subunit. J. Biol. Chem. 1997; 272: 19 794-19 800.
95. 3 subunit. J. Biol. Chem. 1996; 271: 21 978-21 984.
96. 3 complex that binds fibrin but not fibrinogen. Blood 2000; 96: 161-169.
97. Fullard J, Murphy R, O'Neill S, Moran N, Ottridge B, Fitzgerald DJ. A Val93Met mutation in GPIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand. Br. J. Haematol. 2001; 115: 131-139.
98. 3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001; 98: 2432-2441.
99. D'Souza SE, Ginsberg MH, Matsueda GR, Plow EF. A discrete sequence in a platelet integrin is involved in ligand recognition. Nature 1991; 350: 66-68.
100. α 300-312, a presumptive fibrinogen γ-chain binding site on the platelet integrin GPIIb/IIIa, inhibits the adhesion of platelets to at least four adhesive ligands. J. Biol. Chem. 1992; 267: 11 729-11 733.
101. Calvete JJ, Arias J, Alvarez MV, Lopez MM, Henschen A, González Rodríguez J. Further studies on the topography of human platelet glycoprotein IIb. Localization of monoclonal antibody epitopes and the putative glycoprotein IIIa and fibrinogen-binding regions. Biochem. J. 1991; 273: 767-775.
102. Calvete JJ, German R, Schäfer W, McLane MA, Niewiarowski S. Glycoprotein IIb peptide 656-667 mimics the fibrinogen γ chain 402-411 binding site on platelet integrin GPIIb/IIIa. FEBS Lett. 1993; 335: 132-135.
103. 3. Eur. J. Biochem. 2003; 270: 3760-3767.
104. 3. Eur. J. Biochem 2004; 271: 855-862.
105. 3. Biochem. J. 1997; 325: 309-313.
106. 3 on resting platelets and causes resting platelet aggregate formation without platelet shape change. Thromb. Res. 1998; 89 31-40.
107. 3 interacting peptide. Thromb. Haemost. 2001; 86: 894-901.
108. French DL, Coller BS. Hematologically important mutations: Glanzmann thrombasthenia. Blood Cells Mol. Dis. 1997; 23: 39-51.
109. French DL. The molecular genetics of Glanzmann's thrombasthenia. Platelets 1998; 9: 5-20.
110. IIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thromb. Haemost. 2002; 88: 655-662.
111. 747 → Pro) causing thrombasthenic phenotypes in four Japanese patients. Br. J. Haematol. 1998; 102 829-840.
112. Tao J, Arias-Salgado EG, González-Manchón C, Iruin G, Butta N, Ayuso MS, Parrilla R. A 1063G → A mutation in exon 12 of glycoprotein (GP)IIb associated with a thrombasthenic phenotype: mutation analysis of [324E]GPIIb. Br. J. Haematol. 2000; 111: 965-973.
113. Ferrer M, Fernandez-Pinel M, González-Manchón C, González J, Ayuso MS, Parrilla R. A mutant (Arg327 → His) GPIIb associated to thrombasthenia exerts a dominant negative effect in stably transfected CHO cells. Thromb. Haemost. 1996; 76: 292-301.
114. Ruan J, Peyruchaud O, Alberio L, Valles G, Clemetson K, Bourre F, Nurden AT. Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann's thrombasthenia. Br. J. Haematol. 1998; 102: 918-925.
115. Wilcox DA, Paddock CM, Lyman S, Gill SC, Newman PJ. Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association. J. Clin. Invest. 1995; 95: 1553-1560.
116. IIb is responsible for a case of Glanzmann's thrombasthenia. Br. J. Haematol. 2002; 118: 833-835.
117. 3 biogenesis. Blood 2003; 101: 2268-2276.
118. 214Pro mutation produces Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood 1998; 91: 1562-1571.
119. 3 identities a novel region important for ligand binding. Blood 1999; 93: 918-924.
120. 3. Blood 2000; 95: 180-188.
121. 3 are clustered in the β-propeller model. J. Biol. Chem. 2001; 276: 44 275-44 283.
122. Bost KL, Blalock JE. Preparation and use of complementary peptides. Methods Enzymol. 1989; 168: 16-28.
123. Gartner TK, Taylor DB. The amino acid sequence Gly-Ala-Pro-Leu appears to be a fibrinogen binding site in the platelet integrin glycoprotein IIb. Thromb. Res. 1990; 60: 291-309.
124. Gartner TK, Loudon R, Taylor DB. The peptides APLHK, EHIPA and GAPL are hydropathically equivalent peptide mimics of a fibrinogen binding domain of glycoprotein IIb/IIIa. Biochem. Biophys. Res. Commun. 1991; 180: 1446-1452.
125. Gartner TK, Taylor DB. The peptide Glu-His-Ile-Pro-Ala binds fibrinogen and inhibits platelet aggregation and adhesion to fibrinogen and vitronectin. Proc. Soc. Exp. Biol. Med. 1991; 198: 649-655.
126. Gartner TK, Taylor DB, Derrick J. Complementary peptides that interfere with platelet aggregation and adherence. Immunomethods 1994; 5: 148-157.